Circio Holding ASA

CRNA · Oslo Børs · Healthcare

10.70NOK +2.7%last day

Price as of 2 October 2026

The price over the past year, with dividends: +985.4%

Performance

1 month

−12.3%

1 year

+985.4%

3 years, per year

−2.4%

5 years, per year

−40.1%

Largest fall, 3 years

−99.6%

Below the peak now

−98.5%

Volatility, 1 year

181.0%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

5.8

Dividend yield

0.0%

Return on equity

−179.6%

Net margin

–

Market value

305 m USD

Quality, value and trend

Where Circio Holding stands against every Nordic stock today. 100 is best.

Quality49

Profitability and a sound balance sheet over time. Better than 49% of Nordic stocks.

Value2

The price measured against earnings, assets and cash flow. Better than 2% of Nordic stocks.

Trend90

The price development over the past year. Better than 90% of Nordic stocks.

Combined41

Quality, value and trend together. Better than 41% of Nordic stocks.

About Circio Holding

Circio Holding ASA is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 10 employees.

Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a research collaboration with United Immunity Co., Ltd. for the development of vivo CAR-Macrophage (CAR-M) therapy; and Suzhou GenAssist Therapeutics Co., Ltd. to develop circVec-enhanced AAV vectors engineered for in vivo cell therapy and low dose systemic gene therapy.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis